Novo Nordisk experienced its worst stock performance on record this year, triggering the largest leadership overhaul in its centennial history. The company’s share price plunged by roughly half from peak levels reached mid-year, as investors grew skeptical of its ability to monetize breakthroughs in GLP-1 therapies. Revenue growth decelerated to low single digits in the most recent quarter, and guidance for next year was revised downward. In response, the board replaced the long-time CEO and appointed a new executive team tasked with restoring investor confidence and accelerating commercial execution.

Despite investor impatience, Novo Nordisk’s semaglutide franchise continues to demonstrate versatility beyond weight management and glycemic control. Regulatory approvals this year extended its label to include nonalcoholic steatohepatitis and chronic kidney disease in type 2 diabetes patients. Observational studies and small-scale trials suggest potential benefits in reducing cravings for substances such as alcohol and nicotine by modulating dopamine pathways. Although a late-stage Alzheimer’s trial did not meet its primary cognition endpoint, biomarker analyses showed reductions in disease-linked proteins and systemic inflammation markers, fueling plans for prevention-focused studies earlier in disease progression.

Facing patent expiry in China and intensifying competition from both local generics and Eli Lilly’s dual-hormone therapy, Novo Nordisk halved the list price of its obesity therapy in key Chinese provinces. The move aims to maintain patient adherence under public procurement schemes and dissuade early generic adoption when exclusivity ends next spring. Concurrently, the company launched its diabetes GLP-1 injection in India at tiered pricing across three dosage strengths, positioning itself to capture market share in the world’s second-largest type 2 diabetes population. Meanwhile, Eli Lilly has pledged over one billion dollars to build local manufacturing capacity, underscoring the high-stakes rivalry in the Asia-Pacific region.